TPWA
PCRX icon

Twin Peaks Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-106
Closed -$2.4K – 1613
2026
Q1 		$2.4K Buy
+106
New +$2.36K ﹤0.01% 1650
2025
Q3 		– Sell
-105
Closed -$2.6K – 1527
2025
Q2 		$2.6K Buy
+105
New +$2.65K ﹤0.01% 1546

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's PCRX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 106 shares — an estimated $2.4K sold.

Twin Peaks Wealth Advisors first reported a position in PCRX in Q2 2025 and held it in 2 quarters. The position peaked at $2.6K in Q2 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 106 Pacira BioSciences shares in Q2 2026, an estimated $2.4K.
  • Twin Peaks Wealth Advisors first reported a position in Pacira BioSciences in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Pacira BioSciences position peaked at $2.6K in Q2 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.